Overview

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Status:
Recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.

Phase:

Phase 4

Details

Lead Sponsor:

University of Tennessee Graduate School of Medicine

Collaborator:

Mylan Pharmaceuticals

Treatments:

Albuterol
Cholinergic Antagonists
Formoterol Fumarate
Ipratropium